三种抗血管生成药物治疗晚期结直肠癌研究进展

doi:10.3760/cma.j.issn.1673-422X.2015.04.017

摘要/Abstract

摘要： 血管生成在结直肠癌的发生、发展中发挥重要作用。靶向血管内皮生成因子信号通路的药物治疗晚期结直肠癌获得了重要的生存改善。在化疗基础上联合贝伐珠单抗一线、二线和跨线治疗晚期结直肠癌可进一步延长生存期。阿柏西普联合含伊立替康的化疗方案治疗晚期结直肠癌延长了生存期。对抵抗所有化疗药物的晚期结直肠癌患者使用瑞格非尼后仍延长了生存期。这些抗血管生成药物为晚期结直肠癌患者带来了生存获益，并拥有良好的安全性，可以和化疗药物联合用于晚期结直肠癌患者的的治疗。

关键词: 血管生成抑制剂, 结直肠肿瘤, 阿柏西普, 瑞格非尼

Abstract: Angiogenesis plays a vital role in carcinogenesis and development of colorectal cancer. Treatment targeting VEGF signaling pathway acquires important survival prolong for advanced colorectal cancer patients. For advanced colorectal cancer patients, bevacizumab could furtherly prolongs survival time in the setting of first line, second line and continuing therapy after firstprogression therapy combined with chemotherapy. Aflibercept used in combination with irinotecancontaining regimen improves the survival of advanced colorectal cancer patients in secondline setting. Regorafenib also improves the survival of advanced colorectal cancer patients who have progressed after all line treatment. Considering these suivival benefit and their favorable safety, antiangiogenic agents should be taken into all lines of therapy in the management of advanced colorectal cancer.

Key words: Angiogenesis inhibitors, Colorectal neoplasms, Aflibercept, Regorafenib

吴正奇；张志镒；王慧娟；刘小军. 三种抗血管生成药物治疗晚期结直肠癌研究进展[J]. 国际肿瘤学杂志, 2015, 42(4): 301-304.

WU Zheng-Qi-；Zhang-Zhi-Yi-；Wang-Hui-Juan-；Liu-Xiao-Jun. Research progress of three antiangiogenic agents in the treatment of advanced colorectal cancer[J]. Journal of International Oncology, 2015, 42(4): 301-304.

参考文献

［1］ DeSantis CE, Lin CC, Mariotto AB, et al. Cancer treatment and survivorship statistics, 2014［J］. CA Cancer J Clin, 2014, 64(4): 252271. ［2］蔡浩权, 林英城. 不可切除转移性结直肠癌的治疗策略［J］. 国际肿瘤学杂志, 2012, 39(10): 775778. ［3］ Hochster HS, Hart LL, Ramanathan RK, et al. Safety and efficacy of oxaliplatin/fluoropyrimidine regimens with or without bevacizumab as firstline treatment of metastatic colorectal cancer (mCRC): Final analysis of the TREE Study［J］. J Clin Oncol, 2006, 24(21): 35233529. ［4］ Saltz LB, Clarke S, DíazRubio E, et al. Bevacizumab in combination with oxaliplatinbased chemotherapy as firstline therapy in metastatic colorectal cancer: a randomized phase Ⅲ study［J］. J Clin Oncol, 2008, 26(12): 20132019. ［5］ Park MS, Ravi V, Araujo DM. Inhibiting the VEGFVEGFR pathway in angiosarcoma, epithelioid hemangioendothelioma, and hemangiopericytoma/solitary fibrous tumor［J］. Curr Opin Oncol, 22(4): 351355. ［6］ Shibuya M. Vascular endothelial growth factor (VEGF) and its receptor (VEGFR) signaling in angiogenesis a crucial target for antiand proangiogenic therapies［J］. Genes Cancer, 2011, 2(12): 10971105. ［7］ Saif MW. AntiVEGF agents in metastatic colorectal cancer (mCRC): are they all alike?［J］. Cancer Manag Res, 2013, 5: 103115. ［8］ Takahashi S. Vascular endothelial growth factor (VEGF), VEGF receptors and their inhibitors for antiangiogenic tumor therapy［J］. Biol Pharm Bull, 2011, 34(12): 17851788. ［9］ Eichten A, Adler AP, Cooper B, et al. Rapid decrease in tumor perfusion following VEGF blockade predicts longterm tumor growth inhibition in preclinical tumor models［J］. Angiogenesis, 2013, 16(2): 429441. ［10］刘小军, 周永宁, 赵达. 贝伐单抗治疗恶性肿瘤不良反应的策略［J］. 国际肿瘤学杂志, 2011, 38(9): 711714. ［11］ de Gramont A, Van Cutsem E, Schmoll HJ, et al. Bevacizumab plus oxaliplatinbased chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial［J］. Lancet Oncol, 2012, 13(12): 12251233. ［12］ Clarke JM, Hurwitz HI. Targeted therapies: Zivaflibercept: binding to more than VEGFA—does more matter?［J］. Nat Rev Clin Oncol, 2013, 10(1): 1011. ［13］ Dietvorst MH, Eskens FA. Current and novel treatment options for metastatic colorectal cancer: emphasis on aflibercept［J］. Biol Ther, 2013, 3: 2533. ［14］ Mitchell EP. Targeted therapy for metastatic colorectal cancer: role of aflibercept［J］. Clin Colorectal Cancer, 2013, 12(2): 7385. ［15］ Ciombor KK, Berlin J. Aflibercept—a decoy VEGF receptor［J］. Curr Oncol Rep, 2014, 16(2): 17. ［16］ Van Cutsem E, Tabernero J, Lakomy R, et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase Ⅲ randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatinbased regimen［J］. J Clin Oncol, 2012, 30(28): 34993506. ［17］ He K, Cui B, Li G, et al. The effect of antiVEGF drugs (bevacizumab and aflibercept) on the survival of patients with metastatic colorectal cancer (mCRC)［J］. Onco Targets Ther, 2012, 5: 5965. ［18］ Lockhart AC, Rothenberg ML, Dupont J, et al. Phase Ⅰ study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors［J］. J Clin Oncol, 2010, 28(2): 207214. ［19］ Gaya A, Tse V. A preclinical and clinical review of aflibercept for the management of cancer［J］. Cancer Treat Rev, 2012, 38(5): 484493. ［20］ Wilhelm SM, Dumas J, Adnane L, et al. Regorafenib (BAY 734506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity［J］. Int J Cancer, 2011, 129(1): 245255. ［21］ Azad N, Dasari A, Arcaroli J, et al. Phase Ⅰ pharmacokinetic and pharmacodynamic study of cetuximab, irinotecan and sorafenib in advanced colorectal cancer［J］. Invest New Drugs, 2013, 31(2): 345354. ［22］ Mross K, Steinbild S, Baas F, et al. Results from an in vitro and a clinical/pharmacological phase Ⅰ study with the combination irinotecan and sorafenib［J］. Eur J Cancer, 2007, 43(1): 5563. ［23］ Strumberg D, Scheulen ME, Schultheis B, et al. Regorafenib (BAY 734506) in advanced colorectal cancer: a phase Ⅰ study［J］. Br J Cancer, 2012, 106(11): 17221727. ［24］ SartoreBianchi A, Zeppellini A, Amatu A, et al. Regorafenib in metastatic colorectal cancer［J］. Expert Rev Anticancer Ther, 2014, 14(3): 255265. ［25］ Mross K, Frost A, Steinbild S, et al. A Phase Ⅰ doseescalation study of regorafenib (BAY 734506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors［J］. Clin Cancer Res, 2012, 18(9): 26582667. ［26］ Jitawatanarat P, Wee W. Update on antiangiogenic therapy in colorectal cancer: aflibercept and regorafenib［J］. J Gastrointest Oncol, 2013, 4(2): 231238. ［27］ Grothey A, Van Cutsem E, Sobrero A, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebocontrolled, phase 3 trial［J］. Lancet, 2013, 381(9863): 303312.

[1]	张蕊, 褚衍六. 基于FIT与肠道菌群的结直肠癌风险评估模型的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 370-375.
[2]	高凡, 王萍, 杜超, 褚衍六. 肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[3]	王俊毅, 洪楷彬, 纪荣佳, 陈大朝. 癌结节对结直肠癌根治性切除术后肝转移的影响[J]. 国际肿瘤学杂志, 2024, 51(5): 280-285.
[4]	孙国宝, 杨倩, 庄庆春, 高斌斌, 孙晓刚, 宋伟, 沙丹. 结直肠癌肝转移组织病理学生长方式研究进展[J]. 国际肿瘤学杂志, 2024, 51(2): 114-118.
[5]	刘德宝, 孙子雯, 鲁守堂, 徐海东. ASB6在结直肠癌组织中的表达及临床意义[J]. 国际肿瘤学杂志, 2023, 50(8): 470-474.
[6]	陈卓, 陶俊, 陈琳, 柯晶. 外周血miR-194联合粪便miR-143检测对结直肠癌临床筛查的价值[J]. 国际肿瘤学杂志, 2023, 50(5): 268-273.
[7]	黄镇, 张蔡羽天, 柯少波, 石薇, 赵文思, 陈永顺. 结直肠癌患者术后预后模型的构建[J]. 国际肿瘤学杂志, 2023, 50(3): 157-163.
[8]	徐良富, 李袁飞. MSS型结直肠癌肿瘤微环境及免疫联合治疗研究进展[J]. 国际肿瘤学杂志, 2023, 50(3): 186-190.
[9]	刘玉杰, 赵志强, 王子琤. 早期结直肠癌患者外周血单个核细胞中TOP2A、ERBB2的水平及其诊断价值[J]. 国际肿瘤学杂志, 2023, 50(12): 717-722.
[10]	陶红, 殷红, 罗宏, 陶佳瑜. 靶向肿瘤相关巨噬细胞增强结直肠癌免疫检查点抑制剂疗效的潜在策略[J]. 国际肿瘤学杂志, 2023, 50(11): 683-687.
[11]	王熙, 吴川清. 结直肠癌多药耐药逆转的研究进展[J]. 国际肿瘤学杂志, 2023, 50(1): 42-46.
[12]	高一钊, 刘洋, 刘秋龙, 邢金良. 循环游离核酸在结直肠癌临床诊疗中的应用[J]. 国际肿瘤学杂志, 2022, 49(9): 555-559.
[13]	何哲锋, 吴燚阳, 李振军, 应晓江. 炎性相关标志物对结直肠癌的预测价值[J]. 国际肿瘤学杂志, 2022, 49(9): 560-563.
[14]	赵莹, 张革红. AGR、PLR及NLR变化与转移性结直肠癌化疗疗效的相关性研究[J]. 国际肿瘤学杂志, 2022, 49(8): 473-477.
[15]	黄梦盼, 王学红, 芦永福. FOXA2在结直肠癌中的作用机制及其在诊疗中的作用[J]. 国际肿瘤学杂志, 2022, 49(8): 490-493.